These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
462 related articles for article (PubMed ID: 24019381)
1. Personalizing the treatment of pediatric medulloblastoma: Polo-like kinase 1 as a molecular target in high-risk children. Triscott J; Lee C; Foster C; Manoranjan B; Pambid MR; Berns R; Fotovati A; Venugopal C; O'Halloran K; Narendran A; Hawkins C; Ramaswamy V; Bouffet E; Taylor MD; Singhal A; Hukin J; Rassekh R; Yip S; Northcott P; Singh SK; Dunham C; Dunn SE Cancer Res; 2013 Nov; 73(22):6734-44. PubMed ID: 24019381 [TBL] [Abstract][Full Text] [Related]
2. Small molecule kinase inhibitor screen identifies polo-like kinase 1 as a target for neuroblastoma tumor-initiating cells. Grinshtein N; Datti A; Fujitani M; Uehling D; Prakesch M; Isaac M; Irwin MS; Wrana JL; Al-Awar R; Kaplan DR Cancer Res; 2011 Feb; 71(4):1385-95. PubMed ID: 21303981 [TBL] [Abstract][Full Text] [Related]
3. Polo-like kinase 1 inhibition kills glioblastoma multiforme brain tumor cells in part through loss of SOX2 and delays tumor progression in mice. Lee C; Fotovati A; Triscott J; Chen J; Venugopal C; Singhal A; Dunham C; Kerr JM; Verreault M; Yip S; Wakimoto H; Jones C; Jayanthan A; Narendran A; Singh SK; Dunn SE Stem Cells; 2012 Jun; 30(6):1064-75. PubMed ID: 22415968 [TBL] [Abstract][Full Text] [Related]
4. Combined gene expression profiling and RNAi screening in clear cell renal cell carcinoma identify PLK1 and other therapeutic kinase targets. Ding Y; Huang D; Zhang Z; Smith J; Petillo D; Looyenga BD; Feenstra K; Mackeigan JP; Furge KA; Teh BT Cancer Res; 2011 Aug; 71(15):5225-34. PubMed ID: 21642374 [TBL] [Abstract][Full Text] [Related]
5. Targeting sonic hedgehog-associated medulloblastoma through inhibition of Aurora and Polo-like kinases. Markant SL; Esparza LA; Sun J; Barton KL; McCoig LM; Grant GA; Crawford JR; Levy ML; Northcott PA; Shih D; Remke M; Taylor MD; Wechsler-Reya RJ Cancer Res; 2013 Oct; 73(20):6310-22. PubMed ID: 24067506 [TBL] [Abstract][Full Text] [Related]
7. Polo-like kinase 1 is a therapeutic target in high-risk neuroblastoma. Ackermann S; Goeser F; Schulte JH; Schramm A; Ehemann V; Hero B; Eggert A; Berthold F; Fischer M Clin Cancer Res; 2011 Feb; 17(4):731-41. PubMed ID: 21169242 [TBL] [Abstract][Full Text] [Related]
8. Expression, adverse prognostic significance and therapeutic small molecule inhibition of Polo-like kinase 1 in multiple myeloma. Evans RP; Dueck G; Sidhu R; Ghosh S; Toman I; Loree J; Bahlis N; Klimowicz AC; Fung J; Jung M; Lai R; Pilarski LM; Belch AR; Reiman T Leuk Res; 2011 Dec; 35(12):1637-43. PubMed ID: 21816470 [TBL] [Abstract][Full Text] [Related]
9. A sensitized RNA interference screen identifies a novel role for the PI3K p110γ isoform in medulloblastoma cell proliferation and chemoresistance. Guerreiro AS; Fattet S; Kulesza DW; Atamer A; Elsing AN; Shalaby T; Jackson SP; Schoenwaelder SM; Grotzer MA; Delattre O; Arcaro A Mol Cancer Res; 2011 Jul; 9(7):925-35. PubMed ID: 21652733 [TBL] [Abstract][Full Text] [Related]
10. Inhibition of polo-like kinase 1 leads to the suppression of osteosarcoma cell growth in vitro and in vivo. Liu X; Choy E; Harmon D; Yang S; Yang C; Mankin H; Hornicek FJ; Duan Z Anticancer Drugs; 2011 Jun; 22(5):444-53. PubMed ID: 21399492 [TBL] [Abstract][Full Text] [Related]
11. Polo-Like Kinase 1 Pharmacological Inhibition as Monotherapy or in Combination: Comparative Effects of Polo-Like Kinase 1 Inhibition in Medulloblastoma Cells. Pezuk JA; Brassesco MS; Ramos PMM; Scrideli CA; Tone LG Anticancer Agents Med Chem; 2017; 17(9):1278-1291. PubMed ID: 28270075 [TBL] [Abstract][Full Text] [Related]
12. PLK1 is a critical determinant of tumor cell sensitivity to CPT11 and its inhibition enhances the drug antitumor efficacy in squamous cell carcinoma models sensitive and resistant to camptothecins. Zuco V; De Cesare M; Zaffaroni N; Lanzi C; Cassinelli G Oncotarget; 2015 Apr; 6(11):8736-49. PubMed ID: 25826089 [TBL] [Abstract][Full Text] [Related]
13. Polo-like kinase 1: a potential therapeutic option in combination with conventional chemotherapy for the management of patients with triple-negative breast cancer. Maire V; Némati F; Richardson M; Vincent-Salomon A; Tesson B; Rigaill G; Gravier E; Marty-Prouvost B; De Koning L; Lang G; Gentien D; Dumont A; Barillot E; Marangoni E; Decaudin D; Roman-Roman S; Pierré A; Cruzalegui F; Depil S; Tucker GC; Dubois T Cancer Res; 2013 Jan; 73(2):813-23. PubMed ID: 23144294 [TBL] [Abstract][Full Text] [Related]
15. Efficient inhibition of human colorectal carcinoma growth by RNA interference targeting polo-like kinase 1 in vitro and in vivo. Xu WJ; Zhang S; Yang Y; Zhang N; Wang W; Liu SY; Tian HW; Dai L; Xie Q; Zhao X; Wei YQ; Deng HX Cancer Biother Radiopharm; 2011 Aug; 26(4):427-36. PubMed ID: 21797676 [TBL] [Abstract][Full Text] [Related]
16. BI_2536--targeting the mitotic kinase Polo-like kinase 1 (Plk1). Wäsch R; Hasskarl J; Schnerch D; Lübbert M Recent Results Cancer Res; 2010; 184():215-8. PubMed ID: 20072841 [TBL] [Abstract][Full Text] [Related]
17. Current clinical trials with polo-like kinase 1 inhibitors in solid tumors. Yim H Anticancer Drugs; 2013 Nov; 24(10):999-1006. PubMed ID: 23949254 [TBL] [Abstract][Full Text] [Related]
18. Reciprocal activation between PLK1 and Stat3 contributes to survival and proliferation of esophageal cancer cells. Zhang Y; Du XL; Wang CJ; Lin DC; Ruan X; Feng YB; Huo YQ; Peng H; Cui JL; Zhang TT; Wang YQ; Zhang H; Zhan QM; Wang MR Gastroenterology; 2012 Mar; 142(3):521-530.e3. PubMed ID: 22108192 [TBL] [Abstract][Full Text] [Related]
19. Inhibition of Polo-Like Kinase 1 by BI2536 Reverses the Multidrug Resistance of Human Hepatoma Cells In Vitro and In Vivo. Li HY; Luo F; Li XY; Fu XF; He JF; Tian YZ; Zhu JJ; Chu XY; Zhao HL Anticancer Agents Med Chem; 2019; 19(6):740-749. PubMed ID: 30836927 [TBL] [Abstract][Full Text] [Related]
20. Overcoming resistance to Sonic Hedgehog inhibition by targeting p90 ribosomal S6 kinase in pediatric medulloblastoma. Pambid MR; Berns R; Adomat HH; Hu K; Triscott J; Maurer N; Zisman N; Ramaswamy V; Hawkins CE; Taylor MD; Dunham C; Guns E; Dunn SE Pediatr Blood Cancer; 2014 Jan; 61(1):107-15. PubMed ID: 23940083 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]